Compare · ABT vs TRAX
ABT vs TRAX
Side-by-side comparison of Abbott Laboratories (ABT) and First Tracks Biotherapeutics Inc. (TRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and TRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $152.98B, about 239.3x TRAX ($639.2M).
- TRAX has been more active in the news (14 items in the past 4 weeks vs 5 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 8 for TRAX).
- Company
- Abbott Laboratories
- First Tracks Biotherapeutics Inc.
- Price
- $90.56+3.17%
- $18.48+0.82%
- Market cap
- $152.98B
- $639.2M
- 1M return
- +3.08%
- -
- 1Y return
- -32.09%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 14
- Recent ratings
- 25
- 8
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
Latest TRAX
- First Tracks Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Director Schmid John P. converted options into 6,030 shares, increasing direct ownership by 19% to 37,652 units (SEC Form 4)
- Director Marquet Magda converted options into 6,030 shares, increasing direct ownership by 61% to 15,960 units (SEC Form 4)
- Director Jain Rita converted options into 7,330 shares, increasing direct ownership by 62% to 19,194 units (SEC Form 4)
- Director Orwin John A converted options into 6,030 shares, increasing direct ownership by 57% to 16,695 units (SEC Form 4)
- Director Ware J. Anthony converted options into 6,030 shares, increasing direct ownership by 63% to 15,660 units (SEC Form 4)
- Director Fenton Dennis M converted options into 6,030 shares, increasing direct ownership by 121% to 10,995 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Director Fenton Dennis M
- Amendment: SEC Form 4 filed by Director Jain Rita
- Amendment: SEC Form 4 filed by Director Marquet Magda